These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 18785084

  • 1. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
    Rogler G.
    Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
    [No Abstract] [Full Text] [Related]

  • 2. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ.
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract] [Full Text] [Related]

  • 3. Position statement: immunomodulator therapy for inflammatory Bowel disease.
    Lavy A, Chowers Y, Odes HS, Eliakim R, Israel gastroenterology association.
    Isr Med Assoc J; 2003 Mar; 5(3):164-9. PubMed ID: 12725133
    [No Abstract] [Full Text] [Related]

  • 4. General principles of medical therapy of inflammatory bowel disease.
    Friedman S.
    Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
    [Abstract] [Full Text] [Related]

  • 5. Azathioprine and mercaptopurine: lymphoma.
    Prescrire Int; 2011 May; 20(116):126. PubMed ID: 21648178
    [Abstract] [Full Text] [Related]

  • 6. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C, Lichtenstein GR.
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [Abstract] [Full Text] [Related]

  • 7. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
    Schwab M, Herrlinger K, Schaeffeler E, Stange EF.
    Dtsch Med Wochenschr; 2003 Feb 21; 128(8):378-85. PubMed ID: 12594624
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inflammatory bowel disease: management issues during pregnancy.
    Ferrero S, Ragni N.
    Arch Gynecol Obstet; 2004 Sep 21; 270(2):79-85. PubMed ID: 12721680
    [Abstract] [Full Text] [Related]

  • 10. Review article: monitoring of immunomodulators in inflammatory bowel disease.
    Aberra FN, Lichtenstein GR.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):307-19. PubMed ID: 15709982
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive therapy in inflammatory bowel disease.
    Hoang P, Fontaine P, Dalton HR, Gehenot M, Sibille C, Schoonbroodt D, Vanheuverzwyn R.
    Acta Gastroenterol Belg; 1994 Feb 15; 57(5-6):333-8. PubMed ID: 7709704
    [No Abstract] [Full Text] [Related]

  • 12. [Chronic inflammatory bowel diseases. Immunosuppressive drug saves on corticoids].
    MMW Fortschr Med; 1999 Sep 23; 141(38):55. PubMed ID: 10904620
    [No Abstract] [Full Text] [Related]

  • 13. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease.
    Korelitz BI, Reddy B, Bratcher J.
    Expert Opin Drug Saf; 2010 May 23; 9(3):379-82. PubMed ID: 20367524
    [Abstract] [Full Text] [Related]

  • 14. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.
    Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S.
    Aliment Pharmacol Ther; 2008 Sep 15; 28(6):674-88. PubMed ID: 18532990
    [Abstract] [Full Text] [Related]

  • 15. Medical management of the pregnant patient with inflammatory bowel disease.
    Steinlauf AF, Present DH.
    Gastroenterol Clin North Am; 2004 Jun 15; 33(2):361-85, xi. PubMed ID: 15177544
    [Abstract] [Full Text] [Related]

  • 16. Drug resistance in inflammatory bowel diseases.
    Moreau J, Mas E.
    Curr Opin Pharmacol; 2015 Dec 15; 25():56-61. PubMed ID: 26645664
    [Abstract] [Full Text] [Related]

  • 17. [Immunosuppressive agents: Imurel and Purinethol].
    Groupe d'étude thérapeutique des affections inflammatoires digestives.
    Rev Prat; 2005 May 15; 55(9):994. PubMed ID: 16052970
    [No Abstract] [Full Text] [Related]

  • 18. [Chronic inflammatory bowel diseases].
    Herrlinger K, Stange EF.
    Dtsch Med Wochenschr; 2004 Oct 15; 129(42):2241-50; quiz 2251-4. PubMed ID: 15529447
    [No Abstract] [Full Text] [Related]

  • 19. Cutaneous side effects caused by treatment for inflammatory bowel disease.
    Tarabar D, Kandolf-Sekulović L, Tatomirović Ž, Mijušković Ž, Milenković Z, Tarabar O, Pecelj-Broćić T.
    Vojnosanit Pregl; 2016 Apr 15; 73(4):382-9. PubMed ID: 29309107
    [No Abstract] [Full Text] [Related]

  • 20. Review article: remission rates achievable by current therapies for inflammatory bowel disease.
    Peyrin-Biroulet L, Lémann M.
    Aliment Pharmacol Ther; 2011 Apr 15; 33(8):870-9. PubMed ID: 21323689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.